IL10 and myeloid sarcoma: Importantly, these data suggest that, since the capacity of the LPS- or IL-27/LPS-stimulated mDCs to express IL-10 did not differ between the mDCs isolated from HCs or untreated patients with MS, it is not a basis for the differential induction of tolerogenic activity by IL-27.